Osteoporosis and depression are increasingly important health problems in the United States. Reports demonstrating lower bone mineral density and increase fracture risk in patients with depression as compared with those without depression suggest that BMD and depression are related. Whether depression is a risk factor for osteoporosis remains unclear and there are numerous hypotheses about the mechanism of such a potential association. One question involves whether the depression itself or the treatment might be a risk factor for osteoporosis. Recently functional serotonin transporters have been discovered in bone. The clinical implications of this finding are unknown. Serotonin transporters are known to play an important role in depression in that most pharmacologic anti-depressants including selective serotonin reuptake inhibitors (SSRIs) function by blocking this transporter. Thus the serotonin transporter provides a potential link between osteoporosis and depression and anti-depressant treatment. Understanding the impact of serotonin on bone development and loss is important because there are a large number of people treated for depression with medications that alter uptake of serotonin. The objective of this proposal to examine the associations between both clinical depression and treatment with selective serotonin reuptake antagonists (SSRIs) and bone density in humans, to explore the impact of SSRI use on bone turnover and to examine associations between serotonin transporter genotypes and bone mineral density. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23AR051926-02
Application #
7214197
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Mcgowan, Joan A
Project Start
2006-04-01
Project End
2011-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
2
Fiscal Year
2007
Total Cost
$133,864
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Cusano, Natalie E; Maalouf, Naim M; Wang, Patty Y et al. (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98:2734-41
Diem, S J; Harrison, S L; Haney, E et al. (2013) Depressive symptoms and rates of bone loss at the hip in older men. Osteoporos Int 24:111-9
Curtis, Jeffrey R; Ewing, Susan K; Bauer, Douglas C et al. (2012) Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study. J Clin Endocrinol Metab 97:1937-44
Diem, Susan J; Blackwell, Terri L; Stone, Katie L et al. (2011) Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 88:476-84
Warden, Stuart J; Robling, Alexander G; Haney, Elizabeth M et al. (2010) The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 46:4-12
Haney, Elizabeth M; Warden, Stuart J; Bliziotes, M Michael (2010) Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46:13-7
Nelson, Heidi D; Haney, Elizabeth M; Dana, Tracy et al. (2010) Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 153:99-111
Haney, E M; Warden, S J (2008) Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact 8:133-45
Warden, S J; Haney, E M (2008) Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J Musculoskelet Neuronal Interact 8:121-32
Haney, Elizabeth M; Bliziotes, M Michael (2008) Male osteoporosis: new insights in an understudied disease. Curr Opin Rheumatol 20:423-8

Showing the most recent 10 out of 13 publications